The accelerated timeline for eGFR data (Q3 2026) and potential sBLA submission (Q4 2026) is a significant positive catalyst for VERA. Traders should monitor for the eGFR readout in Q3 2026, as positive results would de-risk the path to full approval and could drive substantial upside.
VERA drugs
VERA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $31.26entry
- T+1 · 6mo ago +0.03%α +0.75% · $31.27
- T+5 · 5mo ago +1.76%α +4.72% · $31.81
- T+20 · 5mo ago +36.47%α +38.03% · $42.66
- T+60 · 3mo ago +17.79%α +16.67% · $36.82
Price Chart
How similar events traded
Executive Summary
Vera Therapeutics announced alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy. eGFR results are now expected in Q3 2026, with a supplemental Biologics License Application for full approval planned in Q4 2026, pending results. This accelerates the potential path to full approval for the company's lead asset.
Key Facts
- Aligned with FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy.
- eGFR results now expected in Q3 2026.
- Plans to submit supplemental Biologics License Application for full approval in Q4 2026, pending eGFR results.
- Filing date: June 2, 2026.
Financial Impact
No specific financial figures provided; the event accelerates a key regulatory catalyst for the company's only pipeline asset.
Risk Factors
- eGFR results may not support full approval, leading to significant downside.
- Regulatory timelines could slip, delaying the sBLA submission.
- Competing therapies in IgA Nephropathy could limit atacicept's commercial potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-252475 |
| Document: 0001193125-26-252475-index-headers.html | 0001193125-26-252475 |
| Document: 0001193125-26-252475-index.html | 0001193125-26-252475 |
| Document: 0001193125-26-252475.txt | 0001193125-26-252475 |
Track record
25 reports on VERA
12 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers